What is the current price and volume for ALNOX.PA stock?

ALNOX.PA stock trades at **€0.041** with pre-market volume of **10,209,655** shares, versus an average volume of **4,345,868**, indicating above-normal trading interest.

What drives ALNOX.PA stock price movements?

Price moves are driven by clinical trial readouts, partner collaborations (notably the NOX-A12 program), financing news, and regulatory updates. Sector news can matter, but company catalysts dominate.

How does Meyka AI rate ALNOX.PA stock?

Meyka AI rates ALNOX.PA with a score of **61.94/100 (Grade: B, Suggestion: HOLD)**, based on benchmark, sector, financial growth, key metrics and analyst consensus. This is informational, not financial advice.

What is the Meyka AI forecast for ALNOX.PA stock?

Meyka AI's forecast model projects **€0.11** as a one-year target for ALNOX.PA stock, implying an upside of **168.29%** from **€0.041**. Forecasts are model projections and not guarantees.

EU Stocks

€0.041 NOXXON (ALNOX.PA) EURONEXT pre-market 18 Feb 2026: heavy volume, catalysts

ByHuzaifa Zahoor February 18, 2026February 18, 2026

We see NOXXON Pharma N.V. (ALNOX.PA) trade as one of the most active names in the EURONEXT pre-market on 18 Feb 2026, with the last print at €0.041 and 10,209,655 shares traded so far. The spike in volume, more than twice the average daily flow, is driving focused attention on the ALNOX.PA stock ahead of potential clinical updates and partner-readouts. Traders are watching gaps to the 50-day average (€0.07) and the 200-day average (€0.18) while factoring negative EPS and the Merck collaboration noted in company filings. We summarise technicals, fundamentals, catalysts and a model forecast to help you assess the risk/reward on ALNOX.PA stock.